(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Adamis Pharmaceuticals Corporation, Teva Pharmaceutical, and Advaxis.

The three biggest losers today are Acura Pharmaceuticals, American Superconductor Corporation, and Generac Holdlings.

Winners today

1. Adamis Pharmaceuticals Corporation (ADMP) – 179.02%

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's product candidates comprise Symjepi Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of fluticasone for the treatment of asthma; beclomethasone, a metered dose inhaler product for the asthma; and naloxone injection product candidates for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.

NASDAQ ended the session with Adamis Pharmaceuticals Corporation rising 179.02% to $3.99 on Wednesday, after two sequential sessions in a row of gains. NASDAQ slid 2.17% to $13,973.45, following the last session’s downward trend on what was an all-around negative trend exchanging session today.

Earnings Per Share

As for profitability, Adamis Pharmaceuticals Corporation has a trailing twelve months EPS of $-11.33.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -784.96%.

Yearly Top and Bottom Value

Adamis Pharmaceuticals Corporation’s stock is valued at $3.99 at 17:32 EST, way below its 52-week high of $28.00 and way above its 52-week low of $1.31.

Moving Average

Adamis Pharmaceuticals Corporation’s worth is way above its 50-day moving average of $2.19 and way under its 200-day moving average of $8.86.

Volume

Today’s last reported volume for Adamis Pharmaceuticals Corporation is 20361400 which is 4071.29% above its average volume of 488133.

Revenue Growth

Year-on-year quarterly revenue growth grew by 25.9%, now sitting on 5.05M for the twelve trailing months.

More news about Adamis Pharmaceuticals Corporation.

2. Teva Pharmaceutical (TEVA) – 11.34%

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

NYSE ended the session with Teva Pharmaceutical jumping 11.34% to $9.23 on Wednesday, after three consecutive sessions in a row of losses. NYSE slid 1.05% to $16,184.91, following the last session’s downward trend on what was an all-around bearish trend exchanging session today.

Earnings Per Share

As for profitability, Teva Pharmaceutical has a trailing twelve months EPS of $-1.42.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -17.93%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Teva Pharmaceutical’s EBITDA is 93.61.

Volume

Today’s last reported volume for Teva Pharmaceutical is 27123600 which is 96.79% above its average volume of 13782700.

Moving Average

Teva Pharmaceutical’s worth is way higher than its 50-day moving average of $7.77 and higher than its 200-day moving average of $8.85.

Sales Growth

Teva Pharmaceutical’s sales growth is negative 2% for the present quarter and negative 2.9% for the next.

More news about Teva Pharmaceutical.

3. Advaxis (ADXS) – 7.59%

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.

NASDAQ ended the session with Advaxis jumping 7.59% to $1.17 on Wednesday, following the last session’s upward trend. NASDAQ fell 2.17% to $13,973.45, following the last session’s downward trend on what was an all-around down trend exchanging session today.

Earnings Per Share

As for profitability, Advaxis has a trailing twelve months EPS of $-1.96.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -205.38%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 99.1%, now sitting on 238k for the twelve trailing months.

Volume

Today’s last reported volume for Advaxis is 3923 which is 54.61% below its average volume of 8644.

More news about Advaxis.

4. CDW Corporation (CDW) – 6.97%

CDW Corporation provides information technology (IT) solutions in the United States, the United Kingdom, and Canada. It operates through three segments: Corporate, Small Business, and Public. The company offers discrete hardware and software products and services, as well as integrated IT solutions, including on-premise, hybrid, and cloud capabilities across hybrid infrastructure, digital experience, and security. Its hardware products comprise notebooks/mobile devices, network communications, desktop computers, video monitors, enterprise and data storage, and others; and software products consists of application suites, security, virtualization, operating systems, and network management. The company also provides advisory and design, software development, implementation, managed, professional, configuration, partner, and telecom services, as well as warranties; delivers and manages mission critical software, systems, and network solutions; and implementation and installation, and repair services to its customers through various third-party service providers. It serves government, education, and healthcare customers; and small, medium, and large business customers. CDW Corporation was founded in 1984 and is headquartered in Vernon Hills, Illinois.

NASDAQ ended the session with CDW Corporation rising 6.97% to $200.39 on Wednesday, after two sequential sessions in a row of gains. NASDAQ fell 2.17% to $13,973.45, following the last session’s downward trend on what was an all-around negative trend exchanging session today.

Earnings Per Share

As for profitability, CDW Corporation has a trailing twelve months EPS of $7.98.

PE Ratio

CDW Corporation has a trailing twelve months price to earnings ratio of 25.11. Meaning, the purchaser of the share is investing $25.11 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 88.9%.

More news about CDW Corporation.

5. Waters Corporation (WAT) – 6.66%

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by life science, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.

NYSE ended the session with Waters Corporation rising 6.66% to $292.68 on Wednesday, after five sequential sessions in a row of losses. NYSE fell 1.05% to $16,184.91, following the last session’s downward trend on what was an all-around bearish trend trading session today.

Earnings Per Share

As for profitability, Waters Corporation has a trailing twelve months EPS of $11.46.

PE Ratio

Waters Corporation has a trailing twelve months price to earnings ratio of 25.54. Meaning, the purchaser of the share is investing $25.54 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 141.34%.

More news about Waters Corporation.

6. Aptose Biosciences (APTO) – 6.38%

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

NASDAQ ended the session with Aptose Biosciences jumping 6.38% to $3.50 on Wednesday while NASDAQ slid 2.17% to $13,973.45.

Earnings Per Share

As for profitability, Aptose Biosciences has a trailing twelve months EPS of $-7.08.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -96.45%.

More news about Aptose Biosciences.

7. AFLAC (AFL) – 5.68%

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. It operates in two segments, Aflac Japan and Aflac U.S. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan. The Aflac U.S. segment provides cancer, accident, short-term disability, critical illness, hospital indemnity, dental, vision, long-term care and disability, and term and whole life insurance products in the United States. It sells its products through sales associates, brokers, independent corporate agencies, individual agencies, and affiliated corporate agencies. The company was founded in 1955 and is headquartered in Columbus, Georgia.

NYSE ended the session with AFLAC jumping 5.68% to $76.21 on Wednesday while NYSE fell 1.05% to $16,184.91.

Earnings Per Share

As for profitability, AFLAC has a trailing twelve months EPS of $6.93.

PE Ratio

AFLAC has a trailing twelve months price to earnings ratio of 11. Meaning, the purchaser of the share is investing $11 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.61%.

Yearly Top and Bottom Value

AFLAC’s stock is valued at $76.21 at 17:32 EST, above its 52-week high of $74.02.

Volume

Today’s last reported volume for AFLAC is 2992830 which is 36.45% above its average volume of 2193310.

More news about AFLAC.

8. Humana (HUM) – 5.27%

Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of PBM business. Further, it offers pharmacy solutions, provider services, and home solutions services, such as home health and other services to its health plan members, as well as to third parties. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

NYSE ended the session with Humana rising 5.27% to $482.26 on Wednesday, after four consecutive sessions in a row of gains. NYSE fell 1.05% to $16,184.91, following the last session’s downward trend on what was an all-around negative trend trading session today.

Earnings Per Share

As for profitability, Humana has a trailing twelve months EPS of $24.65.

PE Ratio

Humana has a trailing twelve months price to earnings ratio of 19.56. Meaning, the purchaser of the share is investing $19.56 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.45%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 11.6%, now sitting on 95.64B for the twelve trailing months.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 1.7% and 10.3%, respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Humana’s stock is considered to be oversold (<=20).

Yearly Top and Bottom Value

Humana’s stock is valued at $482.26 at 17:32 EST, way under its 52-week high of $571.30 and way higher than its 52-week low of $423.29.

More news about Humana.

9. Ardelyx (ARDX) – 5.21%

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

NASDAQ ended the session with Ardelyx rising 5.21% to $4.04 on Wednesday while NASDAQ dropped 2.17% to $13,973.45.

Earnings Per Share

As for profitability, Ardelyx has a trailing twelve months EPS of $-0.35.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -69.52%.

Yearly Top and Bottom Value

Ardelyx’s stock is valued at $4.04 at 17:32 EST, way under its 52-week high of $5.13 and way above its 52-week low of $0.69.

Revenue Growth

Year-on-year quarterly revenue growth grew by 2329.3%, now sitting on 63.06M for the twelve trailing months.

Sales Growth

Ardelyx’s sales growth is 504.5% for the ongoing quarter and 348.7% for the next.

Volume

Today’s last reported volume for Ardelyx is 10175200 which is 100.61% above its average volume of 5071930.

More news about Ardelyx.

10. Altisource Portfolio Solutions S.A. (ASPS) – 4.79%

Altisource Portfolio Solutions S.A. operates as an integrated service provider and marketplace for the real estate and mortgage industries in the United States, India, Luxembourg, Uruguay, and internationally. It provides property preservation and inspection services, payment management technologies, and a vendor management oversight software-as-a-service (SaaS) platform. The company also offers Hubzu, an online real estate auction platform, as well as real estate auction, real estate brokerage, and asset management services; and Equator, a SaaS-based technology to manage real estate owned, short sales, foreclosure, bankruptcy, and eviction processes. In addition, it provides mortgage loan fulfillment, certification and certification insurance services, technologies, title insurance agent, settlement, real estate valuation services, residential and commercial construction inspection and risk mitigation, foreclosure trustee, and commercial loan servicing technology services. Further, the company operates TrelixTM Connect, Vendorly, RentRange, REALSynergy, Lenders One Loan Automation, and other platform solutions. It serves financial institutions, government-sponsored enterprises, banks, asset managers, servicers, investors, originators, correspondent lenders, and mortgage bankers. Altisource Portfolio Solutions S.A. was incorporated in 1999 and is headquartered in Luxembourg City, Luxembourg.

NASDAQ ended the session with Altisource Portfolio Solutions S.A. jumping 4.79% to $5.25 on Wednesday, following the last session’s upward trend. NASDAQ dropped 2.17% to $13,973.45, following the last session’s downward trend on what was an all-around negative trend trading session today.

Earnings Per Share

As for profitability, Altisource Portfolio Solutions S.A. has a trailing twelve months EPS of $-3.21.

More news about Altisource Portfolio Solutions S.A..

Losers Today

1. Acura Pharmaceuticals (ACUR) – -33.33%

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.

NASDAQ ended the session with Acura Pharmaceuticals sliding 33.33% to $0.00 on Wednesday while NASDAQ fell 2.17% to $13,973.45.

Earnings Per Share

As for profitability, Acura Pharmaceuticals has a trailing twelve months EPS of $-0.03.

More news about Acura Pharmaceuticals.

2. American Superconductor Corporation (AMSC) – -27.52%

American Superconductor Corporation, together with its subsidiaries, provides megawatt-scale power resiliency solutions worldwide. The company operates in two segments, Grid and Wind. The Grid segment offers products and services that enable electric utilities, industrial facilities, and renewable energy project developers to connect, transmit, and distribute power under the Gridtec Solutions brand; and engineering planning services. It provides transmission planning services, which identify power grid congestion, poor power quality, and other risks; grid interconnection solutions for wind farms and solar power plants, power quality systems, and transmission and distribution cable systems; resilient electric grid systems, resilient electric grid systems; D-VAR systems used for controlling power flow and voltage in the AC transmission system; actiVAR system, a fast-switching medium-voltage reactive compensation solution; armorVAR system installed for reactive compensation, power factor correction, loss reduction, utility bill savings, and mitigation of common power quality concerns related to power converter-based generation and load devices; and D-VAR volt var optimization (VVO) that serves the distribution power grid market. This segment also offers ship protection systems, which reduce a naval ship's magnetic signature; and in board power delivery systems, power generation systems, and propulsion systems; and transformers and rectifiers systems. The Wind segment designs wind turbine systems and licenses these designs to third parties under the Windtec Solutions brand. It supplies power electronics and software-based control systems, engineered designs, and support services; and provides customer support services to wind turbine manufacturers. This segment's design portfolio comprises a range of drivetrains and power ratings of 2 megawatts and higher. The company was incorporated in 1987 and is headquartered in Ayer, Massachusetts.

NASDAQ ended the session with American Superconductor Corporation sliding 27.52% to $11.69 on Wednesday while NASDAQ fell 2.17% to $13,973.45.

Earnings Per Share

As for profitability, American Superconductor Corporation has a trailing twelve months EPS of $-1.21.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -36.66%.

Volume

Today’s last reported volume for American Superconductor Corporation is 15830000 which is 1275.77% above its average volume of 1150630.

More news about American Superconductor Corporation.

3. Generac Holdlings (GNRC) – -25.02%

Generac Holdings Inc. designs, manufactures, and sells power generation equipment, energy storage systems, energy management devices and solutions, and other power products for the residential, light commercial, and industrial markets worldwide. The company offers residential automatic standby generators, automatic transfer switch, air-cooled engine residential standby generators, and liquid-cooled engine generators; residential storage solution consists of a system of batteries, an inverter, photovoltaic optimizers, power electronic controls, and other components; Mobile Link, a remote monitoring system for home standby generators; smart home solutions, such as smart thermostats and a suite of home monitoring products; smart water heater controllers; residential clean energy solutions; and portable and inverter generators; outdoor power equipment, including trimmers, field and brush mowers, log splitters, stump grinders, chipper shredders, lawn and leaf vacuums, and pressure washers and water pumps; and battery-powered turf care products. It also provides commercial and industrial products comprising cleaner-burning natural gas fueled generators; light-commercial standby generators and related transfer switches; stationary generators and related transfer switches; single-engine industrial generators; industrial standby generators; industrial transfer switches; light towers, mobile generators, and mobile energy storage systems; and aftermarket service parts and product accessories. The company distributes its products through independent residential dealers, industrial distributors and dealers, national and regional retailers, e-commerce partners, electrical, HVAC and solar wholesalers, catalogs, equipment rental companies and distributors, and solar installers; and directly to end users. The company was founded in 1959 and is headquartered in Waukesha, Wisconsin.

NYSE ended the session with Generac Holdlings falling 25.02% to $115.00 on Wednesday while NYSE dropped 1.05% to $16,184.91.

Earnings Per Share

As for profitability, Generac Holdlings has a trailing twelve months EPS of $4.04.

PE Ratio

Generac Holdlings has a trailing twelve months price to earnings ratio of 28.47. Meaning, the purchaser of the share is investing $28.47 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.96%.

Sales Growth

Generac Holdlings’s sales growth is negative 24.3% for the present quarter and 1.7% for the next.

More news about Generac Holdlings.

4. SmileDirectClub (SDC) – -18.49%

SmileDirectClub, Inc., an oral care company, offers clear aligner therapy treatment. The company manages the end-to-end process, which include marketing, aligner manufacturing, fulfillment, treatment by a customer's dentist or orthodontist, and facilitating remote clinical monitoring through a network of orthodontists and general dentists through its proprietary teledentistry platform, SmileCheck in the United States, Puerto Rico, Canada, Australia, the United Kingdom, New Zealand, Ireland, Hong Kong, Germany, Singapore, France, Spain, and Austria. It also offers aligners, impression and whitening kits, whitening gels, and retainers; and toothbrushes, toothpastes, water flossers, SmileSpa, and various ancillary oral care products. The company was founded in 2014 and is headquartered in Nashville, Tennessee.

NASDAQ ended the session with SmileDirectClub dropping 18.49% to $0.89 on Wednesday, after three sequential sessions in a row of gains. NASDAQ fell 2.17% to $13,973.45, following the last session’s downward trend on what was an all-around negative trend exchanging session today.

Earnings Per Share

As for profitability, SmileDirectClub has a trailing twelve months EPS of $-2.628.

More news about SmileDirectClub.

5. Credit Acceptance Corporation (CACC) – -13.87%

Credit Acceptance Corporation engages in the provision of financing programs, and related products and services to independent and franchised automobile dealers in the United States. The company advances money to automobile dealers in exchange for the right to service the underlying consumer loans; and buys the consumer loans from the dealers and keeps the amount collected from the consumers. It is also involved in the business of reinsuring coverage under vehicle service contracts sold to consumers by dealers on vehicles financed by the company. The company was incorporated in 1972 and is headquartered in Southfield, Michigan.

NASDAQ ended the session with Credit Acceptance Corporation sliding 13.87% to $476.36 on Wednesday while NASDAQ dropped 2.17% to $13,973.45.

Earnings Per Share

As for profitability, Credit Acceptance Corporation has a trailing twelve months EPS of $30.95.

PE Ratio

Credit Acceptance Corporation has a trailing twelve months price to earnings ratio of 15.39. Meaning, the purchaser of the share is investing $15.39 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.12%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 3% and 27%, respectively.

Sales Growth

Credit Acceptance Corporation’s sales growth is 1.4% for the present quarter and 3.7% for the next.

Volume

Today’s last reported volume for Credit Acceptance Corporation is 147191 which is 137.48% above its average volume of 61979.

Volatility

Credit Acceptance Corporation’s last week, last month’s, and last quarter’s current intraday variation average was 0.54%, 0.41%, and 1.63%.

Credit Acceptance Corporation’s highest amplitude of average volatility was 0.98% (last week), 1.25% (last month), and 1.63% (last quarter).

More news about Credit Acceptance Corporation.

6. Lumen Technologies (LUMN) – -13.05%

Lumen Technologies, Inc., a facilities-based technology and communications company, provides various integrated products and services under the Lumen, Quantum Fiber, and CenturyLink brands to business and residential customers in the United States and internationally. The company operates in two segments, Business and Mass Markets. It offers compute and application services, such as edge cloud services, IT solutions, unified communication and collaboration solutions, colocation and data center services, content delivery services, and managed security services; and IP and data services, including VPN data network, Ethernet, internet protocol (IP), and voice over internet protocol. The company also provides fiber infrastructure services comprising high bandwidth optical wavelength networks; and unlit optical fiber and related professional services. In addition, it offers voice and other services, including private line services, a direct circuit or channel specifically dedicated for connecting two or more organizational sites; a portfolio of traditional time division multiplexing voice services; and synchronous optical network-based ethernet, legacy data hosting services, and conferencing services. The company was formerly known as CenturyLink, Inc. and changed its name to Lumen Technologies, Inc. in September 2020. The company was incorporated in 1968 and is headquartered in Monroe, Louisiana.

NYSE ended the session with Lumen Technologies dropping 13.05% to $1.77 on Wednesday while NYSE fell 1.05% to $16,184.91.

Earnings Per Share

As for profitability, Lumen Technologies has a trailing twelve months EPS of $-1.55.

Volatility

Lumen Technologies’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.41%, a negative 1.25%, and a positive 4.35%.

Lumen Technologies’s highest amplitude of average volatility was 3.49% (last week), 4.49% (last month), and 4.35% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Lumen Technologies’s stock is considered to be oversold (<=20).

More news about Lumen Technologies.

7. Exact Sciences (EXAS) – -10.05%

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

NASDAQ ended the session with Exact Sciences falling 10.05% to $86.75 on Wednesday, after two sequential sessions in a row of losses. NASDAQ dropped 2.17% to $13,973.45, following the last session’s downward trend on what was an all-around negative trend exchanging session today.

Earnings Per Share

As for profitability, Exact Sciences has a trailing twelve months EPS of $-2.92.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -16.36%.

Volatility

Exact Sciences’s last week, last month’s, and last quarter’s current intraday variation average was 0.13%, 0.13%, and 1.87%.

Exact Sciences’s highest amplitude of average volatility was 1.47% (last week), 1.49% (last month), and 1.87% (last quarter).

Earnings Before Interest, Taxes, Depreciation, and Amortization

Exact Sciences’s EBITDA is -258.98.

Previous days news about Exact Sciences

• Here's what key metrics tell us about exact sciences (exas) Q2 earnings. According to Zacks on Tuesday, 1 August, "For the quarter ended June 2023, Exact Sciences (EXAS Quick QuoteEXAS – Free Report) reported revenue of $622.09 million, up 19.3% over the same period last year. ", "Here is how Exact Sciences performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"

More news about Exact Sciences.

8. QuantumScape (QS) – -9.35%

QuantumScape Corporation, a development stage company, focuses on the development and commercialization of solid-state lithium-metal batteries for electric vehicles and other applications. QuantumScape Corporation was founded in 2010 and is headquartered in San Jose, California.

NYSE ended the session with QuantumScape sliding 9.35% to $11.35 on Wednesday, after two successive sessions in a row of losses. NYSE slid 1.05% to $16,184.91, following the last session’s downward trend on what was an all-around negative trend exchanging session today.

Earnings Per Share

As for profitability, QuantumScape has a trailing twelve months EPS of $-0.97.

Volume

Today’s last reported volume for QuantumScape is 10030800 which is 36.25% above its average volume of 7361510.

Previous days news about QuantumScape

• : ev-battery maker quantumscape names new president. According to MarketWatch on Monday, 31 July, "EV-battery maker QuantumScape Corp. on Monday and a veteran of the semiconductor and data-storage industries, to the newly created role of president. "

More news about QuantumScape.

9. Plug Power (PLUG) – -9.23%

Plug Power Inc. delivers end-to-end clean hydrogen and zero-emissions fuel cell solutions for supply chain and logistics applications, on-road electric vehicles, stationary power market, and others in North America and internationally. It engages in building an end-to-end green hydrogen ecosystem, including liquid green hydrogen production, storage and handling, transportation, and dispensing infrastructure. The company offers GenDrive, a hydrogen-fueled proton exchange membrane (PEM) fuel cell system that provides power to material handling electric vehicles; GenFuel, a liquid hydrogen fueling delivery, generation, storage, and dispensing system; GenCare, an ongoing Internet of Things-based maintenance and on-site service program for GenDrive fuel cell systems, GenSure fuel cell systems, GenFuel hydrogen storage and dispensing products, and ProGen fuel cell engines; and GenSure, a stationary fuel cell solution that offers modular PEM fuel cell power to support the backup and grid-support power requirements of the telecommunications, transportation, and utility sectors. It also provides GenKey, an integrated turn-key solution for transitioning to fuel cell power; ProGen, a fuel cell stack and engine technology used in mobility and stationary fuel cell systems, and as engines in electric delivery vans; Liquefaction systems; and Electrolyzers that are hydrogen generators optimized for clean hydrogen production. The company sells its products through a direct product sales force, original equipment manufacturers, and dealer networks. Plug Power Inc. was founded in 1997 and is headquartered in Latham, New York.

NASDAQ ended the session with Plug Power sliding 9.23% to $11.58 on Wednesday, following the last session’s downward trend. NASDAQ slid 2.17% to $13,973.45, following the last session’s downward trend on what was an all-around negative trend trading session today.

Earnings Per Share

As for profitability, Plug Power has a trailing twelve months EPS of $-1.27.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.43%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 49.3%, now sitting on 770.92M for the twelve trailing months.

Moving Average

Plug Power’s worth is way higher than its 50-day moving average of $10.20 and below its 200-day moving average of $12.74.

Yearly Top and Bottom Value

Plug Power’s stock is valued at $11.58 at 17:32 EST, way under its 52-week high of $31.56 and way above its 52-week low of $7.39.

More news about Plug Power.

10. Johnson Controls (JCI) – -8.67%

Johnson Controls International plc, together with its subsidiaries, engages in engineering, manufacturing, commissioning, and retrofitting building products and systems in the United States, Europe, the Asia Pacific, and internationally. It operates in four segments: Building Solutions North America, Building Solutions EMEA/LA, Building Solutions Asia Pacific, and Global Products. The company designs, sells, installs, and services heating, ventilating, air conditioning, controls, building management, refrigeration, integrated electronic security, integrated fire detection and suppression systems, and fire protection and security products for commercial, industrial, retail, small business, institutional, and governmental customers. It also provides energy efficiency solutions and technical services, including inspection, scheduled maintenance, and repair and replacement of mechanical and control systems, as well as data-driven smart building solutions to non-residential building and industrial applications. In addition, the company offers control software and software services for residential and commercial applications. Johnson Controls International plc was incorporated in 1885 and is headquartered in Cork, Ireland.

NYSE ended the session with Johnson Controls dropping 8.67% to $63.96 on Wednesday, after two sequential sessions in a row of gains. NYSE slid 1.05% to $16,184.91, following the last session’s downward trend on what was an all-around negative trend exchanging session today.

Earnings Per Share

As for profitability, Johnson Controls has a trailing twelve months EPS of $1.99.

PE Ratio

Johnson Controls has a trailing twelve months price to earnings ratio of 32.14. Meaning, the purchaser of the share is investing $32.14 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.1%.

More news about Johnson Controls.

Stay up to date with our winners and losers daily report